Array BioPharma is an American clinical stage, pharmaceutical company that focuses ononcologymedication headquartered inBoulder, Colorado. The company is currently a subsidiary ofPfizer after being acquired for $11 billion in 2019.

In 1998, the company was founded by Drs. Tony Piscopio, Kevin Koch, David Snitman, and K.C. Nicolaou.^[1]

In November 2000, the company became apublic company via aninitial public offering.^[2]

In June 2019,Pfizer acquired the company for approximately $11 billion.^[3]

• MEKTOVI (Binimetinib) - selective MEK inhibitor - Approved 2018, acquired byPfizer
• TUKYSA (Tucatinib) - HER2 inhibitor - Approved 2020, owned bySeagen (Seattle Genetics)
• BRAFTOVI (Encorafenib) - BRAF inhibitor - Approved 2018, acquired byPfizer
• KRAZATI (Adagrasib) - KRasG12C mutation inhibitor - Approved 2022, collaboration withMirati Therapeutics
• KOSELUGO (Selumetinib) - MEK1/2 inhibitor - Approved 2020, licensed byAstrazeneca
• VITRAKVI (Larotrectinib) - TRK Inhibitor - Approved 2018, licensed byLoxo Oncology (Eli Lilly)

• 1998 establishments in Colorado
• 2000 initial public offerings
• 2019 mergers and acquisitions
• American companies established in 1998
• Pharmaceutical companies established in 1998
• Biotechnology companies established in 1998
• Pharmaceutical companies of the United States
• Companies formerly listed on the Nasdaq
• Biotechnology companies of the United States
• Health care companies based in Colorado
• Companies based in Boulder, Colorado
• Pfizer
• Pharmaceutical companies